ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
FOXP1 exacerbates allergic rhinitis progression by mediating ferroptosis in nasal mucosal epithelial cells via transcriptional regulation of SDHAF2.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the role of the transcription factor FOXP1 and its target gene SDHAF2 in allergic rhinitis (AR), as well as their regulatory effects on ferroptosis in nasal epithelial cells.
methodsAn AR mouse model and IL-4/IL-13-induced human nasal epithelial cells (HNEpCs) were used. Gene and protein expression, cytokine secretion, ferroptosis markers, nasal pathology, and AR symptoms were assessed via transcriptome sequencing, qRT-PCR, Western blot, ELISA, dual-luciferase reporter assay, co-immunoprecipitation, detection of Fe
resultsSdhaf2 was significantly upregulated in AR models and closely associated with mitochondrial function and ferroptosis. Knockdown of SDHAF2 inhibited IL-4/IL-13-induced ferroptosis and inflammation in HNEpCs, whereas overexpression of SDHAF2 aggravated these phenotypes. The above changes could be modulated by Erastin or Ferrostatin-1. FOXP1 was highly expressed in AR models and transcriptionally regulated SDHAF2, which was verified by dual-luciferase reporter assays. SDHAF2 interacted with ALOX15 to increase ALOX15 expression and promote ferroptosis. Additional overexpression of ALOX15 reversed the inhibitory effect of SDHAF2 knockdown on ferroptosis. In OVA-induced AR mice, Sdhaf2 knockdown relieved nasal symptoms, reduced inflammatory cytokines, improved nasal pathological lesions and suppressed ferroptosis, and these protective effects were partially abolished by Erastin.
conclusionFOXP1 upregulates SDHAF2. The encoded SDHAF2 protein interacts with ALOX15 to facilitate ferroptosis in nasal epithelial cells, thereby aggravating AR progression. The FOXP1/SDHAF2/ALOX15/ferroptosis axis may serve as a novel therapeutic target for AR.
Indexed as
Identifiers
42700237What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.